Completed trials

Gleevec (imatinib) – This trial evaluated the efficacy and safety of an oral dose of ST1571 for diffuse patients with lung fibrosis.

P144 – This trial evaluated the efficacy and safety of the topical application of the drug ‘’P144’’ for skin fibrosis in patients with scleroderma. We are still awaiting results of un-blinded data.

SStep – This six year trial started in 2002 looking at the use of iloprost tablets in lowering the incidence of heart attacks and angina. Un-blinded study results will be given to study participants on 31 May 2011 at a meeting at the Royal Free Hospital.

GTN Study – This Raynaud’s trial involved the use of a topical gel formation of Nitro-glycerine MQX-503, and matching placebo, to prevent Raynauds phenomenon.

TADELAFIL – This is an extension study to evaluate the long-term safety and efficacy of Tadalafil in the treatment of patients with pulmonary arterial hypertension. We are still awaiting drug licence.

TRIUMPH – This is an extension study to find out the effect of Treprostinil inhalation in the management of severe pulmonary arterial hypertension. This drug has not been licensed in Europe, currently used in USA.

ARIES – A study of Ambrisentan in pulmonary arterial hypertension (PAH). The purpose of this study was to determine if ambrisentan was safe and to assess the effectiveness of two different doses of ambrisentan in the treatment of PAH. This trial led to the licensing of ambrisentan and it has now been used in over 9,000 patients worldwide.

INNOVUS – An observational study aimed at examining the treatment pathways, clinical characteristics and health care resource utilization associated with PAH or CTEPH.

EARLY – The main purpose of the study was to find out the effectiveness of Bosentan in patients with mildly symptomatic PAH. This showed that early treatment improves six minute walking distance and breathlessness.

EARLY LONG TERM DATA – Patients in this study were followed until at least half of the patients have had the opportunity to be exposed to Bosentan for at least 5 years.

SITEZANTAN – The trial led to licensing of this drug in pulmonary hypertension. However, it has been withdrawn world-wide because of rare side effects in the liver.